Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05798897 | Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma(APOLLO) | recruiting | Phase 1 | 79 | Marker Therapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06137144 | AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.(PRIMAVERA) | recruiting | Phase 1 / Phase 2 | 161 | AstraZenecaINDUSTRY | 11 | Sep 14, 2026 |
| clinicaltrials |
| NCT05272384 | Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | recruiting | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07444632 | Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies | recruiting | Phase 1 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06383338 | A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.(PEGASUS) | recruiting | Phase 1 | 10 | Murdoch Childrens Research InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05857969 | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | recruiting | Phase 1 | 65 | Florida International UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07451054 | CD45BE-HSPC + CART-45 Cells | recruiting | Phase 1 | 42 | University of PennsylvaniaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05092451 | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances | recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06090864 | ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells | recruiting | Phase 1 / Phase 2 | 31 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06150664 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | recruiting | Phase 1 | 85 | Compass TherapeuticsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07020533 | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant | recruiting | Phase 1 | 46 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06176690 | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas(CABAL2) | recruiting | Phase 1 | 90 | Baylor College of MedicineOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT02332668 | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | recruiting | Phase 1 / Phase 2 | 370 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
| NCT04664179 | EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma(CILESTE) | recruiting | Phase 1 | 52 | Baylor College of MedicineOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03681561 | Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 54 | Veronika BachanovaOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02917083 | CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)(RELY-30) | recruiting | Phase 1 | 60 | Baylor College of MedicineOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07623850 | A Phase I Study of JLM019 Injection(JLM019) | recruiting | Phase 1 | 115 | Jecho Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04491370 | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 20 | New York Medical CollegeOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06487624 | An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors | recruiting | Phase 1 | 50 | FBD Biologics LimitedINDUSTRY | 3 | Apr 13, 2026 | clinicaltrials |
| NCT05544968 | Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies | recruiting | Phase 1 | 42 | Medical College of WisconsinOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT01555892 | Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE(GRALE) | recruiting | Phase 1 | 136 | Baylor College of MedicineOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT02508038 | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors | recruiting | Phase 1 | 22 | University of Wisconsin, MadisonOTHER | 1 | Oct 16, 2025 | clinicaltrials |
| NCT06299462 | PTCy and ATG for MSD and MUD Transplants | recruiting | Phase 1 / Phase 2 | 50 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06642792 | A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 280 | AkesoINDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05476770 | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | recruiting | Phase 1 | 54 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Dec 6, 2024 | clinicaltrials |
| NCT06494371 | A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma | recruiting | Phase 1 | 32 | Ruijin HospitalOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT02259556 | CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas(CART30) | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials